Finding. Thirty to 120 minutes after APX2014, pancreatic cancer cells have not rewritten their proteome. They have rewritten their marks. Cysteine oxidation arrives first and stays; phosphorylation spreads; lysine acetylation lags. The earliest consistent pathways are mitochondrial translation, electron transport, TCA metabolism, and mitochondrial redox control — and mitochondria then use TCA substrates less well.
Why this paper matters
Ref-1/APE1 is a two-faced enzyme: DNA repair and redox-dependent transcription. The APX series (APX3330 in trials; APX2014 as a second-generation redox inhibitor) is meant to cut the redox signaling that PDAC uses for growth, resistance, and metabolic adaptation. What has been missing is the first hour: what actually changes before mRNA and protein abundance move.
Gampala, Li, Trejo, Kelley and colleagues run that clock with a multiplexed PTM workflow — abundance, cysteine oxidation, phosphorylation, acetylation — in Pa03C cells. Minimal abundance change is the quality-control win. If protein levels are still, the PTM waves are not just cell death.
Mitochondria are the early object
Pathway integration does not wander into generic stress. It lands on mitochondrial translation, respiratory electron transport, TCA-cycle metabolism, and mitochondrial redox homeostasis. That ranking is then checked with substrate-utilization assays: TCA fuels are handled worse after drug. Nuclear clients are not ignored — NF-κB1 and p53 pick up coordinated oxidation, phospho, and acetyl marks in important domains — but the earliest systems map is organellar.
This is the correct grain for a redox-targeted drug. Transcription-factor narratives skip the mitochondria; metabolomics alone skips the sites. Multi-PTM proteomics sits in between.
How far to trust it
One line, one acute window, no in-vivo PD. Cysteine oxidation can be off-target chemistry as easily as regulated signaling. The abstract asserts selectivity for the Ref-1 redox function; a brief cannot re-litigate that medicinal-chemistry claim. Mitotic-organization effects are later and could be secondary to energy or ROS.
Score is high-80s because the method is serious and the mitochondrial early-response claim is specific. Confidence stays medium until the site lists are public and a second model repeats the TCA defect.
What to extract
If you ingest PTM datasets, this is a priority download: cysteine sites on mitochondrial ribosomes and ETC/TCA proteins, plus the NF-κB1/p53 multi-mark overlap. If you follow Ref-1 therapeutics, treat mitochondrial redox remodeling as the opening move of APX2014, not a late metabolic side effect.